|4.||Stomach Neoplasms (Stomach Cancer)
|5.||Ovarian Neoplasms (Ovarian Cancer)
|1.||Arroyo, Vicente: 28 articles (01/2013 - 01/2002)|
|2.||Wong, Florence: 22 articles (03/2015 - 01/2003)|
|3.||Sehouli, Jalid: 20 articles (12/2015 - 01/2004)|
|4.||Ginès, Pere: 20 articles (06/2013 - 03/2002)|
|5.||Jiménez, Wladimiro: 19 articles (01/2016 - 02/2002)|
|6.||Bernardi, Mauro: 18 articles (01/2015 - 10/2002)|
|7.||Bendtsen, Flemming: 16 articles (05/2015 - 12/2007)|
|8.||Tsianos, Epameinondas V: 16 articles (07/2012 - 04/2005)|
|9.||Diamandis, Eleftherios P: 15 articles (01/2014 - 05/2003)|
|10.||Yagasaki, Kazumi: 15 articles (01/2010 - 01/2002)|
02/01/2015 - "Most patients (77.6%) completely cleared the ascites without diuretics, but many achieved this beyond 2 years. "
03/01/1998 - "Improvement of ascites after TIPS were associated with a significant reduction in the dose of diuretics. "
01/01/2006 - "Through a better understanding of the pathophysiology of ascites formation and the mechanism of action of diuretics, improved extracellular fluid balance can be achieved in these patients."
03/01/1995 - "Clinical improvement in ascites control was noted in 74%, and the mean dose of diuretics was decreased by more than 50%. "
04/01/1999 - "Albumin is effective in improving the rate of response and preventing recurrence of ascites in cirrhotic patients with ascites receiving diuretics. "
|2.||Paclitaxel (Taxol)FDA LinkGeneric
05/01/2008 - "In vitro release studies of paclitaxel from the implant were conducted in various fluids including human ascites fluid. "
05/01/2014 - "Three cycles of weekly paclitaxel were successfully administered, leading to the disappearance of malignant ascites. "
12/01/2011 - "The concentration of paclitaxel in the ascites was maintained between 0.01 μM and 0.05 μM until 72 hours. "
12/01/2011 - "Also, the concentration of paclitaxel in the ascites was measured. "
12/01/2010 - "Moreover, chemosensitivity of cells isolated from solid tumour and ascites from the same patient did not show any significant difference with exaption of paclitaxel."
|3.||Cisplatin (Platino)FDA LinkGeneric
10/01/2010 - "Cisplatin administration in the peritoneal cavity is thus very effective in preventing progression of ascites."
03/01/1995 - "To study the effect of thermotolerance on cellular cisplatin (cDDP) sensitivity at 37 degrees C and 43 degrees C in cell lines with different cDDP sensitivities, two Ehrlich ascites tumour cell lines (one with high cDDP sensitivity and one with in vitro acquired cDDP resistance) were used. "
02/01/1983 - "Effect of cisplatin on the plasma membrane phosphatase activities in ascites sarcoma-180 cells: a cytochemical study."
11/01/2013 - "After he received an S-1 plus cisplatin( CDDP) regimen for 6 courses, the primary lesion and ascites had disappeared. "
11/01/2011 - "[A novel Cisplatin delivery system for malignant ascites-bearing mice-a basic experimentation]."
04/01/1995 - "In conclusion, TIPS is useful in the treatment of refractory ascites through lowering portal pressure and improving renal sodium excretion. "
10/01/2004 - "Modifying MELD, by including points for persistent ascites and low serum sodium, improved prediction of early pretransplant mortality in low MELD score patients. "
02/01/2000 - "There is improved understanding of the mechanism of ascites formation and the pathophysiology of the renal sodium retention that accompanies portal hypertensive ascites. "
03/01/1999 - "Adequate intravascular filling in ascites-free cirrhotic patients with normal portal pressure permits an improved but not normalized renal response to a sodium load, possibly due to persistently elevated sympathetic activity. "
08/01/1998 - "In conclusion, URO improved sodium and urine output in cirrhotic patients with and without ascites by enhancing fluid delivery from the proximal tubules in addition to inhibiting fractional sodium reabsorption in the distal nephron."
|5.||Aminocaproic Acids (EAC)FDA LinkGeneric
01/01/2013 - "The newly synthesized complex resulted in inhibition of proliferation of EAC cells and ascites formation. "
05/01/2012 - "The synthesized complexes resulted in inhibition of proliferation of EAC cells and ascites formation. "
01/01/2012 - "EESM caused a significant (p < 0.01) decrease in ascites volume, packed cell volume and viable cell count, and also prolonged the life span of EAC tumour-bearing mice. "
10/01/2007 - "One day after the last injection half of the mice with EAC were sacrificed and antitumor activity was assessed by means of ascites volume inhibition. "
07/01/1991 - "In the presence of ascites fluid in the culture medium, EAC cells progressed through G1 and S phases but accumulated in G2. "
|6.||Spironolactone (Aldactone)FDA LinkGeneric
05/01/1980 - "Following surgery, these patients were placed on a loop-blocking diuretic plus Aldactone, and prompt diuresis ensued with gradual improvement in the ascites. "
03/01/1997 - "Five patients (three in the placebo and two in the spironolactone group) abandoned the treatment prior to ascites recurrence or the end of the study due to complications or lack of compliance. "
05/14/1961 - "[Trials of treatment of cirrhotic ascites with a spirolactone. "
02/01/2013 - "The main treatment of ascites is with spironolactone, in combination with a loop diuretic where indicated. "
08/01/2003 - "Since spironolactone alone requires less dose adjustment, it would be more suitable for treating ascites on an outpatient basis."
|7.||Furosemide (Lasix)FDA LinkGeneric
01/01/2011 - "Patients with anasarca responded well to oral and intravenous furosemide, but those with isolated ascites did not. "
04/01/2012 - "Use of a short continuous furosemide infusion can achieve a FENa of 1% or greater in patients with cirrhotic ascites and may be safe and efficacious for diuresis, meriting further study."
12/01/2005 - "This study shows that HRS as defined by the International Ascites Club can be treated by albumin administration alone or with furosemide given according to the patient's specific need using CVP."
12/01/1967 - "Studies on furosemide: an effective oral saludiuretic for bilharzial ascites."
10/25/1965 - "[Clinical trials of a new salidiuretic, furosemide, in the treatment of cirrhotic ascites. "
02/01/1997 - "Aldosterone concentrations were significantly higher in the serum (2609 +/- 374 pg/ml) than in the ascites (2025 +/- 347 pg/ml) (P = 0.015). "
04/01/1986 - "A low ascites to plasma ratio was found for aldosterone (0.023 +/- 0.023), but not for AVP (0.71 +/- 0.82). "
09/01/1984 - "In particular, nine cirrhotics with ascites showed a significantly lowered ratio of UkalV to urinary aldosterone excretion when compared with eight cirrhotics without ascites. "
04/15/1978 - "A highly significant increase of PRA, PRC, AT II and plasma aldosterone was observed in treated cirrhotics with (group II) or without (group III) ascites. "
08/01/1962 - "[Treatment of cirrhotic ascites by an inhibitor of aldosterone synthesis]."
05/15/2012 - "In the prospective study of actual 15 LDLT, using VP-RL with types B and C, size and number of venous reconstructions, and functional GV and postoperative parameters, such as postoperative serum total bilirubin levels and ascites volume, were significantly improved compared with those using M-RL (P<0.05). "
07/01/2009 - "A meso-caval shunt was performed, after which the ascites resolved, serum bilirubin normalized and the synthetic function of the liver improved. "
09/01/1996 - "The remaining three patients had less advanced disease and demonstrated decreases in serum bilirubin, improvement in coagulopathy, and decreased ascites after TIPS. "
11/01/2003 - "Natural history studies have identified several variables associated with survival, particularly age, bilirubin, albumin, prothrombin time, ascites, encephalopathy, and advanced histological stage. "
09/22/2001 - "In our study, age, an increase in bilirubin level, presence of ascites, and marital status (single, widowed or separated) were associated with a significantly lower survival rate in chronic alcoholics."
|10.||Fluorouracil (Carac)FDA LinkGeneric
05/01/1994 - "But after continuous nocturnal 5-FU therapy, a significant reduction in ascites was noted. "
06/01/2004 - "Sequential MTX/5FU therapy is effective against AGC with malignant ascites with acceptable toxicity and warrants further investigations in a phase III setting."
01/01/2015 - "SL-A002 demonstrated significant dose-dependent antitumor activity in the Sarcoma-180 (S-180) ascites model with peak effect produced at the dose of 120 mg/kg (i.p.) with inhibition of 89.36% compared to 97.96% for 5-FU (20 mg/kg i.p.). "
02/01/2011 - "Assessing gene expression would be useful in predicting 5-FU sensitivity for patients with malignant ascites."
05/01/2010 - "Blood and ascites samples were collected at different times to detect 5-FU quantity by HPLC. "
|1.||Drug Therapy (Chemotherapy)
06/01/2012 - "After successful percutaneous stenting and placement of an internal-external drainage tube from the biliary tree to the gastric ventricle, ascites and cholascos resolved completely and the patient was then referred for chemotherapy. "
06/01/2006 - "The KPS of the responders was improved significantly (P < 0.001), and the response of malignant ascites to intraperitoneal chemotherapy was demostrated as an independent prognostic factor by multi-variate analysis in this series. "
01/01/2012 - "Is palliative laparoscopic hyperthermic intraperitoneal chemotherapy effective in patients with malignant hemorrhagic ascites?"
06/01/2006 - "In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites is simple, effective and safe, which can improve the KPS and prognosis of the responders."
10/21/2015 - "Meanwhile, a new concept, "Clinical Benefit Response in GC (CBR-GC)", was recently introduced to measure the efficacy of chemotherapy for malignant ascites of GC. "
|2.||Surgical Portasystemic Shunt (Portosystemic Shunt)
11/01/1997 - "The reintroduction of paracentesis and the recent introduction of the transjugular intrahepatic portosystemic shunt (TIPS) are the most relevant innovations in the treatment of ascites during the past two decades, although controlled trials in large series of patients are needed to delineate whether TIPS is a safe and useful treatment for these patients."
03/01/2002 - "Transjugular percutaneous intrahepatic portosystemic shunt (IPS) is associated with a marked decrease in portal pressure and consequently this technique has been used in the treatment of refractory ascites. "
10/01/2005 - "Several trials showed that uncovered transjugular intrahepatic portosystemic shunt (TIPS) is superior to paracentesis for the control of refractory ascites. "
10/01/1998 - "This study suggests that patients with medically refractory ascites treated with transjugular intrahepatic portosystemic shunt (TIPS) may have improved in overall clinical status. "
10/01/2015 - "For patients with recurrent disease or graft rejection needing large volume paracentesis, the use of a transjugular intrahepatic portosystemic shunt may serve as a bridge to more definitive treatment (retransplant), although it may not be as effective for managing ascites as splenic artery embolization, arguably underused, which is emerging as a potential alternative treatment option. "
02/01/2011 - "Here, we describe a case of malignant ascites managed by insertion of a Tenckhoff Catheter (TC), which resulted in successful symptomatic control and improvement in quality of life."
11/01/2011 - "Radiologically placed tunneled peritoneal catheter is safe and effective in palliation of symptomatic malignant ascites."
11/01/2010 - "Although the low number of patients in our series precludes generalizations, tunneled peritoneal catheters seem to be a safe and effective minimally invasive treatment for malignant ascites in terminal oncologic patients. "
01/01/1999 - "Tenckhoff catheter can be useful in the management of intractable malignant ascites."
08/01/2014 - "Safety and efficacy of the PleurX catheter for the treatment of malignant ascites."
05/01/2002 - "Percutaneous placement of peritoneovenous shunt is a safe, fast, and inexpensive procedure, extremely useful in resolution of refractory ascites, reducing symptoms, and allowing effective palliation, with a great improvement in quality of life."
05/01/1981 - "An accurately placed LeVeen shunt dramatically relieves intractable ascites with improvement in renal function, nutrition, and general health. "
04/01/1984 - "In recent years, implantation of a peritoneo-venous shunt has proven effective in the treatment of therapy-resistant ascites. "
02/01/2011 - "Persistent ascites can be effectively treated by peritoneovenous shunts."
09/19/1991 - "The LeVeen shunt and paracentesis are equally effective in relieving refractory ascites. "
02/01/2015 - "Ascites clearance is dependent on number of TIPS revision, whereas survival is predicted by younger age, complete response, and covered stent use, although era effect likely contributed to improved survival with covered stent use."
01/01/2014 - "The patient underwent angiographic stent placement, and the ascites markedly improved after the procedure. "
05/04/1995 - "Thrombotic occlusion of the stent shunt occurred within two weeks in 5 patients, and later insufficiency of the shunt occurred in 16 patients, including 12 with recurrence of ascites after complete remission. "
03/01/2004 - "All symptom scores were significantly improved after stent placement (p < 0.001) and with the exception of ascites, remained significantly improved (p < 0.05) until the last follow-up. "
04/01/2011 - "Transjugular intrahepatic portosystemic stent shunt is an effective treatment for chronic ascites. "